)
Visual
test
AN2 Therapeutics
AN2 Therapeutics (ANTX) investor relations material
AN2 Therapeutics Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Evercore ISI 8th Annual HealthCONx Conference summary3 Dec, 2025
Strategic pivots and pipeline evolution
Major transition in 2025 following a phase III readout for epetraborole in NTM lung disease, leading to a shift in focus and learnings for future NTM strategies.
Expanded therapeutic focus to oncology in 2024, leveraging boron chemistry platform.
Entered the clinic with a novel compound for Chagas disease and exploring additional opportunities.
Cash runway extends into early 2028, supporting a compact team and multiple programs.
Oncology program highlights
Two lead oncology assets: ENPP1 inhibitor (innate immune response, tumor microenvironment) and PI3K alpha inhibitor (pan mutant, wild-type sparing, high selectivity).
Boron chemistry enables highly potent, selective compounds with favorable PK profiles.
ENPP1 program shows synergy with checkpoint inhibitors and DNA-damaging agents.
PI3K compound demonstrates superior selectivity margins compared to competitors.
Preclinical phase expected to last 6–9 months, with clinical entry anticipated soon.
Infectious disease pipeline and priorities
Abscessus program (NTM lung disease) targets a $1B+ US market with no FDA-approved drugs; oral agent epetraborole moving toward NDA filing.
Chagas disease program features a novel, 100% curative compound in non-human primates; phase I well underway, with phase II planned.
Melioidosis program addresses a high-mortality infection, eligible for non-dilutive funding and PRV.
Abscessus trial is a significant, investigator-led 90-patient study supporting phase III initiation.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- APAM
AUM hit $180B, strong returns and Grandview deal drove growth despite equity outflows. - GM
Disciplined transformation, resilient supply chains, and strategic EV focus drive robust results. - BTBT
Transitioned to a strategic asset model with major stakes in Ethereum and AI infrastructure. - PSX
Q4 2025 earnings hit $2.9B, with record refining yields and strong portfolio transformation. - ARCC
FY 2025 delivered $2.01 Core EPS, $1.86 net income/share, and a $0.48 Q1 2026 dividend. - HMN
Record core earnings, 12.4% ROE, and 10% EPS growth guidance for 2026. - AFG
Record underwriting profit, strong ROE, and over $700M returned to shareholders in 2025. - OXBR
Tokenized reinsurance contracts on Solana open Florida's market to global investors. - PNDORA
2025 organic growth reached 6%, with EBIT margin at 23.9% and cautious 2026 outlook. - PRU
Earnings rose 12% to $6.6B; Japan sales pause to cut 2026 earnings by $300M-$350M.
Next AN2 Therapeutics earnings date
Q4 202525 Mar, 2026
AN2 Therapeutics
Next AN2 Therapeutics earnings date
Q4 202525 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
AN2 Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases. The company specializes in novel small-molecule therapies designed to address unmet medical needs, particularly in non-tuberculous mycobacterial (NTM) lung disease and other bacterial infections. The company is headquartered in Menlo Park, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage